Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.
Department of Radiation Effects, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.
Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):813-818. doi: 10.1016/j.ijrobp.2020.09.053. Epub 2020 Nov 13.
Radiation therapy (RT) modulates the immune characteristics of the tumor microenvironment (TME). It is not known whether these effects are dependent on the type of RT used.
We evaluated the immunomodulatory effects of carbon-ion therapy (CiRT) compared with biologically equivalent doses of photon therapy (PhRT) on solid tumors. Orthotopic 4T1 mammary tumors in immunocompetent hosts were treated with CiRT or biologically equivalent doses of PhRT. Seventy-two hours after RT, tumors were harvested and the immune characteristics of the TME were quantified by flow cytometry and multiplex cytokine analyses.
PhRT decreased the abundance of CD4+ and CD8+ T cells in the TME at all doses tested, with compensatory increases in proliferation. By contrast, CiRT did not significantly alter CD8+ T-cell infiltration. High-dose CiRT increased secretion of proinflammatory cytokines by tumor-infiltrating CD8+ T cells, including granzyme B, IL-2, and TNF-α, with no change in IFN-γ. Conversely, high-dose PhRT increased CD8+ T-cell secretion of IFN-γ only. At most of the doses studied, PhRT increased proliferation of immunosuppressive regulatory T cells; this was only seen with high-dose CiRT. Cytokine analyses of bulk dissociated tumors showed that CiRT significantly increased levels of IFN-γ, IL-2, and IL-1β, whereas PhRT increased IL-6 levels alone.
At low doses, lymphocytes differ in their sensitivity to CiRT compared with PhRT. Unlike PhRT, low-dose CiRT is generally lymphocyte-sparing. At higher doses, CiRT is a more potent inducer of proinflammatory cytokines and merits further study as a modulator of the immunologic characteristics of the TME.
放射治疗(RT)可调节肿瘤微环境(TME)的免疫特征。目前尚不清楚这些影响是否取决于所使用的 RT 类型。
我们评估了与光子治疗(PhRT)等效生物学剂量的碳离子治疗(CiRT)对实体瘤的免疫调节作用。在免疫活性宿主中,用 CiRT 或等效生物学剂量的 PhRT 治疗 4T1 原位乳腺肿瘤。RT 后 72 小时,收获肿瘤,并通过流式细胞术和多重细胞因子分析量化 TME 的免疫特征。
PhRT 在所有测试剂量下均降低了 TME 中 CD4+和 CD8+T 细胞的丰度,同时伴有增殖的代偿性增加。相比之下,CiRT 对 CD8+T 细胞浸润没有显著影响。高剂量 CiRT 增加了肿瘤浸润性 CD8+T 细胞分泌的促炎细胞因子,包括颗粒酶 B、IL-2 和 TNF-α,而 IFN-γ 没有变化。相反,高剂量 PhRT 仅增加 CD8+T 细胞 IFN-γ 的分泌。在大多数研究剂量下,PhRT 增加了免疫抑制调节性 T 细胞的增殖;只有高剂量 CiRT 才会出现这种情况。对大块分离肿瘤的细胞因子分析表明,CiRT 显著增加了 IFN-γ、IL-2 和 IL-1β 的水平,而 PhRT 仅增加了 IL-6 的水平。
在低剂量下,淋巴细胞对 CiRT 和 PhRT 的敏感性不同。与 PhRT 不同,低剂量 CiRT 通常对淋巴细胞有保护作用。在更高剂量下,CiRT 是一种更有效的促炎细胞因子诱导剂,值得进一步研究作为 TME 免疫特征调节剂。